Status and phase
Conditions
Treatments
About
GSK615915A is being developed as a novel surfactant for use in the formulation of GSK's future generation of Metered Dose Inhalers (MDIs). A surfactant in a MDI would provide a more stable drug suspension, this in turn will produce a consistent dose of drug being delivered with each puff.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
The subject must be clinically stable The subject has a baseline FEV1 = 80% of predicted.
Exclusion criteria
46 participants in 6 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal